EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Seyedehsan Navabi 1
Geert R. D'Haens 2
Karen Samaan 3
Xingyuan Li 3
Vipin Arora 3
Isabel Redondo 3
Silvio Danese 4
1 Rutgers New Jersey Medical School, Newark, United States
2 Amsterdam University Medical Centers, Amsterdam, Netherlands
3 Eli Lilly and Company, Indianapolis, United States
4 IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
Topic
Endoscopy, Histopathology, IBD
Session
IL-23-Blockers in IBD: Part 2
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]